BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
The device enters the U.S. market with established clinical and physician experience in Europe.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BD (BDX) announced the U.S. commercial launch of its Liverty TIPS Stent Graft for patients with complications of portal hypertension. TIPS is a minimally invasive procedure that creates a new blood-flow pathway in the liver to relieve pressure.
BD says the system is designed to help physicians tailor treatment to individual anatomy and clinical needs. The launch is supported by six-month interim results from the prospective, multicenter ARCH study involving 177 patients; no numerical clinical outcomes were provided.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The launch of the Liverty™ TIPS Stent Graft gives physicians flexibility to tailor treatment for patients.
TIPS is a minimally invasive procedure used to create a new pathway for blood flow in the liver, helping relieve pressure caused by portal hypertension, a condition that can lead to serious complications such as internal bleeding or fluid buildup in the abdomen. TIPS procedures are used to manage conditions such as variceal bleeding and refractory ascites, but can vary significantly based on patient anatomy, disease progression and treatment goals. The Liverty™ TIPS Stent Graft is designed to address this variability by enabling a more tailored, patient-specific approach to therapy.
"The Liverty™ TIPS Stent Graft was designed to give physicians more flexibility during TIPS procedures," said Rob Righi, vice president and general manager of the Vascular Platform, Peripheral Intervention at BD. "By offering the longest length TIPs stent graft on the market and tailored shunt diameter sizing, the system helps physicians make real-time treatment decisions for patients with complications of portal hypertension."
For clinicians, key features of the Liverty™ TIPS Stent Graft include:
- Expandable diameter design (6-10 mm) to address patient-specific hemodynamics;
- Covered stent lengths ranging from 4 to 10 cm—the longest commercially available—to support varied anatomies;
- Fully sheathed, tri-axial delivery system, designed for deployment accuracy, control and ease-of-use;
- Highly visible radiopaque markers and a marker band to aid in visualization and accurate placement under fluoroscopy; and
- Delivery system that allows for sheath-less tracking through the liver parenchyma.
According to Dr. Ziv Haskal, principal investigator of the ARCH trial and professor of radiology and surgery at the University of Virgina, "I've helped develop a lot of existing TIPS technology. Device innovation is intended to advance every operator's daily expertise. What stands out using the Liverty™ TIPS Stent Graft is the unique ease of delivering the device into position and controlling it during deployment. The ability to accommodate the new range of intended TIPS diameters and longer lengths will help physicians best tailor treatment to each patient."
With
For more information about the Liverty™ TIPS Stent Graft, visit bd.com/Liverty.
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
|
Contacts: |
|
|
Media |
Investors |
|
Matt Marcus |
Shawn Bevec SVP, Investor Relations |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-advances-portal-hypertension-care-in-the-us-with-support-for-more-personalized-treatment-options-302920969.html
SOURCE BD (Becton, Dickinson and Company)